National Blood Foundation Scientific Research Grants Program
National Blood Foundation Scientific Research Grants Program Submit the application by 11:59pm ET December 31, 2014. Application fee of $150 must accompany the application unless the primary investigator is an AABB individual member. The National Blood Foundation annually awards grants for one or two-year research projects, with a maximum award per grant of $75,000. NBF is pleased to announce the availability of funding in 2015 for scientific research projects related to transfusion medicine and cellular therapies. NBF will award grants for investigator-initiated original research in all aspects of blood banking, transfusion medicine, cellular therapies and patient blood management. Important areas of research for the grant program include: IMMUNOLOGY Alloimmunization, immune modulation, and tolerance Animal models for the study of graft-vs-host disease Biology of autoimmune hemolytic anemia HEMATOLOGY Autologous and allogeneic stem cell transplants Detection of residual disease following stem cell transplants Effects of growth factors in vitro and in vivo Biochemistry of coagulation factors IMMUNOHEMATOLOGY Blood group serology Biochemistry of red cell antigens Molecular genetics of the blood groups INFECTIOUS DISEASES Studies on Lyme disease, West Nile Virus, SARS and babesiosis and other emerging diseases Effect of allogeneic transfusion in HIV-infected and immunocompromised patients Improved detection of transfusion - transmitte...
Authors: Musio F Abstract INTRODUCTION: Anemia has and will continue to be a central theme in medicine particularly as clinicians are treating a burgeoning population of complex multi-organ system processes. As a result of multiple randomized controlled trials (RCTs), meta-analyses, and societal recommendations overly restrictive paradigms and under-administration of erythropoiesis stimulating agents (ESAs) have likely been followed by clinicians among all specialties. AREAS COVERED: A review of anemia in the context of chronic kidney disease, hematologic malignancies and cancer is presented with focus on the e...
Publication date: Available online 9 October 2020Source: Mutation Research/Reviews in Mutation ResearchAuthor(s): Klaudia Kulczynska-Figurny, James J. Bieker, Miroslawa Siatecka
CONCLUSIONS: Immunohistochemistry seems to be a promising option not only in clinical recognition, but also in the selection and monitoring of treatment effects. However, these methods have not yet recommended for routine clinical use. PMID: 33032462 [PubMed - as supplied by publisher]
Publication date: Available online 9 October 2020Source: Reumatología Clínica (English Edition)Author(s): Lina María Saldarriaga Rivera, Daniel Fernández Ávila, Wilson Bautista Molano, Daniel Jaramillo Arroyave, Alain Jasaf Bautista Ramírez, Adriana Díaz Maldonado, Jorge Hernán Izquierdo, Edwin Jáuregui, María Constanza Latorre Muñoz, Juan Pablo Restrepo, Juan Sebastián Segura Charry
CONCLUSION: This study found that childhood cancer survivors in New Zealand had a high prevalence of developmental dental abnormalities and it identified potential risk factors related to their cancer treatment. Inequitable access to oral rehabilitation for this patient group argues for a mechanism for consistent improved access to publicly funded dental care across district health boards in New Zealand. PMID: 33032302 [PubMed - in process]
Authors: Zhao N, Xiang Q, Liu Z, Zhao X, Cui Y Abstract INTRODUCTION: There remains an unmet need for better anticoagulants. The phase I clinical trial is of great significance in the development of anticoagulants, and the design is special. This system review aims to provide insights for the design of future phase I clinical trials of anticoagulants. AREAS COVERED: We searched the database PubMed and ClinicalTrail.gov website, to collate the phase I clinical trial of anticoagulants in healthy people. The study protocol, inclusion exclusion criteria, safety and pharmacodynamic indexes were reviewed. EXPERT ...
Authors: Hui KK PMID: 33034297 [PubMed - as supplied by publisher]
Publication date: Available online 9 October 2020Source: Neurología (English Edition)Author(s): G. Alvarez Bravo, L. RamióTorrentà
Publication date: Available online 9 October 2020Source: Neurología (English Edition)Author(s): N. Morollón, R. Belvís, A. De Dios, N. Pagès, C. González-Oria, G. Latorre, S. Santos-Lasaosa
CONCLUSIONS: The SMs in PWIBDs and a craniotomy performed immediately before starting the process of determining brain death seem to be related to lengthening the TT-BD. PMID: 33029974 [PubMed]
More News: Allergy & Immunology | Anemia | Autoimmune Disease | Babesiosis | Biochemistry | Biology | Bleeding | Funding | Genetics | Grants | Hematology | Infectious Diseases | Lyme Disease | Molecular Biology | PET Scan | Research | SARS | Stem Cell Therapy | Stem Cells | Study | Training | Transplants | Universities & Medical Training | West Nile Virus